1
DOI:
https://doi.org/10.18413/rrpharmacology.12.1169Аннотация
1
Графическая аннотация
Ключевые слова:
osteoporosis, zoledronic acid, resveratrolБиблиографические ссылки
Aaron N, Costa S, Rosen CJ, Qiang L (2022) The implications of bone marrow adipose tissue on inflammaging. Frontiers in Endocrinology 13: 853765. https://doi.org/10.3389/fendo.2022.853765 [PubMed] [PMC]
Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, Kirkland JL, van Deursen JM (2011) Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479(7372): 232–236. https://doi.org/10.1038/nature10600 [PubMed] [PMC]
Camacho PM (Ed) (2019) Metabolic Bone Diseases: A Case Based Approach. Cham: Springer, 268 pp. ISBN 978-3-030-03693-5.
Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG (2019) Pharmacology of bisphosphonates. British Journal of Clinical Pharmacology 85(6): 1052–1062. https://doi.org/10.1111/bcp.13867 [PubMed] [PMC]
Daponte V, Henke K, Drissi H (2024) Current perspectives on the multiple roles of osteoclasts: mechanisms of osteoclast–osteoblast communication and potential clinical implications. eLife 13: e95083. https://doi.org/10.7554/eLife.95083 [PubMed] [PMC]
Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone 27(1): 13–20. https://doi.org/10.1016/S8756-3282(00)00284-2 [PubMed]
Jin ZH, Wang SF, Liao W (2020) Zoledronic acid accelerates osteogenesis of bone marrow mesenchymal stem cells by attenuating oxidative stress via the SIRT3/SOD2 pathway and thus alleviates osteoporosis. European Review for Medical and Pharmacological Sciences 24(4): 2095–2101. https://doi.org/10.26355/eurrev_202002_20389 [PubMed]
Knyazkova II (2014) Clinical pharmacology of bisphosphonates. Medicines of Ukraine [Liki Ukrainy] 5–6: 84–89. [in Russian]
Kos M (2015) Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Archives of Medical Science 11(2): 319–324. https://doi.org/10.5114/aoms.2015.50964 [PubMed] [PMC]
Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral and Maxillofacial Surgery 61(9): 1115–1117. https://doi.org/10.1016/S0278-2391(03)00720-1 [PubMed]
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. Journal of Clinical Endocrinology & Metabolism 90(3): 1294–1301. https://doi.org/10.1210/jc.2004-0952 [PubMed] [PMC]
Rozhinskaya LY, Lutsenko AS (2021) Report on the International Symposium on Osteoporosis. Osteoporosis and Bone Diseases [Osteoporoz i Osteopatii] 24(3): 33–35. [in Russian]
Spevak EM, Tsymbal AN (2017) Bisphosphonate osteonecrosis of the jaws: current state of the problem. Kazan Medical Journal [Kazanskiy Meditsinskiy Zhurnal] 98(1): 91–95. [in Russian]
Strukov VI, Vinogradova OP, Sergeeva-Kondrachenko MY, Yarygina EG, Kotelnikova EV, Elizarova OV, Selyatitskaya VG (2022) Immunotherapy of postmenopausal osteoporosis and other diseases of the osteoarticular system against the background of hormonal deficiency. Obstetrics and Gynecology [Akusherstvo i Ginekologiya] 10(2): 47–55. [in Russian]
Vasiliev GV, Novikov OO, Kochkarov VI, Pokrovskii MV, Artyushkova EB, Beskhmelnitsyna EA (2007) Pharmacological characteristics of resveratrol. Kursk Scientific and Practical Bulletin "Man and His Health" [Kurskiy Nauchno-Prakticheskiy Vestnik "Chelovek i ego Zdorovye"] 3: 97–104. [in Russian]
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2026 Shevchenko OA, Dolzhikov AA, Gudyrev OS

Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Русский
English
